Use of biologics for the treatment of moderate-to-severe asthma: the age of personalized medicine.
Curr Opin Pulm Med
; 28(3): 266-273, 2022 05 01.
Article
em En
| MEDLINE
| ID: mdl-35131991
ABSTRACT
PURPOSE OF REVIEW There are multiple FDA-approved biologics to treat poorly controlled moderate-to-severe asthma. Given the heterogeneity of asthma and the lack of head-to-head data between biologics, selecting the best biologic for a patient can be difficult. This review summarizes the key literature to date, in hopes of facilitating an evidence-based approach to selecting the most appropriate biologic for patients with asthma. RECENT FINDINGS:
In addition to unique mechanisms of action, there is increasing literature on predictors of response to each biologic, such as sensitizations to aeroallergens, peripheral eosinophil count, total serum IgE, and exhaled nitric oxide. Biologics available for asthma are also being increasingly studied in comorbid conditions with asthma, and this may facilitate selecting the most appropriate biologic for a patient. In the absence of head-to-head studies, there is literature of switching between biologics whenever necessary.SUMMARY:
The authors outline an approach to selecting a biologic based on various considerations, and hope this suggested approach facilitates selecting the biologic most suitable for each individual with poorly controlled moderate-to-severe asthma.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Asma
/
Produtos Biológicos
/
Antiasmáticos
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article